Loading...
XJPX
7774
Market cap200mUSD
Oct 09, Last price  
793.00JPY
1D
1.93%
1Q
22.76%
Jan 2017
-45.27%
IPO
78.60%
Name

Japan Tissue Engineering Co Ltd

Chart & performance

D1W1MN
XJPX:7774 chart
P/E
—
P/S
14.75
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-0.67%
Revenues
2.18b
-11.11%
103,000,000111,000,000114,000,000211,659,000351,574,000473,606,000563,704,0001,008,045,0001,321,495,0001,430,826,0002,135,149,0002,271,507,0002,357,918,0002,309,851,0002,257,609,0002,103,443,0002,032,448,0002,514,190,0002,455,474,0002,182,745,000
Net income
-735m
L+187.79%
-916,000,000-1,086,000,000-1,133,000,000-1,099,917,000-1,156,986,000-1,096,366,000-1,077,686,000-827,837,000-690,527,000-681,539,000276,242,000227,890,000-333,248,000-287,099,000-466,622,000-497,889,000-729,317,000143,169,000-255,304,000-734,751,000
CFO
-488m
L+228.93%
-775,000,000-981,718,000-1,021,897,000-1,021,005,000-1,012,151,000-1,059,155,000-989,987,000-961,316,000-756,725,000-346,907,00054,950,000632,006,000-396,110,000-84,584,000-399,586,000-225,248,000-622,600,000274,138,000-148,365,000-488,020,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.

Key people

Toshihiro Osuka
Senior Managing Executive Officer, Director · since 2021
Michiyo Aiba
Executive Officer, Director of Pharmaceutical Affairs · since 2024
Miho Fujita
Executive Officer, Director of Manufacturing · since 2025
Shigeaki Hayashi
Executive Officer, Director of Clinical Development · since 2025
Hiroaki Murai
Executive Officer, Director of Infrastructure Development Promotion · since 2025
Yoshihide Ninagawa
Executive Officer, Director of Research and Development Support Business · since 2025
Norio Sakakibara
Executive Officer, Director of New Business · since 2025
Akinobu Wakabayashi
Executive Officer, Director of Business Administration, Director · since 2025
Tadae Yazaki
Director of Sales, Executive Officer · since 2025
Kazuto Yamada
Executive President, Representative Director · since 2025
Takayuki Nakano
Non-Executive Director · since 2021
Yasuo Kitajima
Independent Director · since 2023
Toshiyuki Masai
Independent Director · since 2022
URL
http://www.jpte.co.jp
IPO date
Dec 21, 2007
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT